Summarize the key details about this patient

Summary of Alan Stucchi's Clinical Case

Patient Overview

Alan Stucchi is a 40-year-old man from Milan, Italy diagnosed with glioblastoma multiforme (GBM) - the most aggressive type of brain cancer (WHO Grade IV) - at age 39 in 2024. Despite his serious diagnosis, he maintains excellent physical function with minimal symptoms beyond mild speech hesitation.

Current Medical Situation

Disease Status:

• Recurrent and progressive multifocal disease (meaning the cancer has returned and is growing in multiple areas of the brain)
• Tumors located in:
  • Left frontal region
  • Left temporal region
  • Right frontal area
  • Corpus callosum (the structure connecting the brain's two hemispheres)
• Recent seizure activity with associated bleeding inside one tumor

Treatment Journey:

• 2024: Two brain surgeries (craniotomies) with complete tumor removal, followed by standard chemotherapy (temozolomide) and radiation
• May 2025: First recurrence (2 tumors) → treated with Cyberknife stereotactic radiosurgery (precise radiation) + Regorafenib (targeted therapy)
• September 2025: Two additional new tumors appeared
• October 2025: Further progression on imaging
• Current: Lomustine chemotherapy recommended as next treatment

Critical Challenges

Medical:

• Rapid disease progression despite aggressive treatment (recurrence every 3-6 months)
• Limited standard treatment options remaining
• Molecular testing (NGS) pending - this could identify specific genetic mutations that might be targeted with newer therapies

Emotional & Family:

• Married to Feby (primary caregiver) with a 5-year-old son
• Family experiencing profound distress about limited options
• Son frequently asks "if his papa will be ok"
• Significant frustration with current oncology team's approach

Family's Active Response

The family demonstrates exceptional engagement and medical literacy:

• Researching clinical trials globally
• Seeking multiple expert opinions
• Considering alternative treatments (including expensive programs in Mexico)
• Working with Cancer Commons navigation team
• Arranging comprehensive molecular testing through Protean BioCare

Key Concerns Requiring Attention

According to NCCN Guidelines for Central Nervous System Cancers, recurrent glioblastoma requires individualized treatment approaches. The document highlights several urgent needs:

1. Second opinion consultation - family expressing dissatisfaction with current care recommendations

2. Clinical trial access - patient's excellent functional status (ECOG PS 0) makes him eligible for many trials

3. Molecular profiling completion - essential for identifying potential targeted therapy options

4. Additional treatment considerations:

   • Tumor Treating Fields (Optune device) - FDA-approved for recurrent GBM
   • Integrative approaches supported by research centers like UCSF
   • Combination therapies (imipramine + bevacizumab)

5. Family support services - addressing caregiver burden and providing resources for their young son

Bottom Line

Alan represents a challenging but not hopeless case: a young patient with aggressive recurrent glioblastoma who maintains excellent physical function, supported by a highly engaged family actively seeking all possible treatment options. The American Cancer Society emphasizes that clinical trials often provide access to promising new approaches for recurrent GBM, making trial enrollment a critical consideration for patients like Alan.

The family's proactive approach and Alan's maintained functional status create opportunities for exploring experimental treatments and clinical trials that might not be available through standard care pathways alone.